Risk Model for Predicting Gaps in Surgical Oncology Care Among Patients With Stage I-III Rectal Cancer From KwaZulu-Natal, South Africa
JCO Global Oncology · 2025
DOI: 10.1200/go-24-00480 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Yoshan Moodley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Cancer Research Group, Department of Surgery, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: Rectal Neoplasms, Surgical Oncology. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Gaps in surgical oncology care (GISOC), including delayed or nonreceipt of surgery, are detrimental to cancer control. This research sought to develop a risk model for predicting GISOC in South African rectal cancer (RC) patients with localized disease. METHODS This retrospective cohort study analyzed data from an existing colorectal cancer patient registry. GISOC was defined as surgery received >62 days after diagnosis with stage I-III RC or nonreceipt of surgery for stage I-III RC. Patient demographics, comorbidity, disease staging, and neoadjuvant therapy receipt were included as covariates in the analysis. A supervised logistic regression machine learning algorithm was used to train and test an appropriate risk model, which was translated into a nomogram. Receiver operating characteristic curve analyses and AUC assessments were used to establish the nomogram's performance. RESULTS The analysis included 490 patients (training data set = 245, testing data set = 245). Overall, there were 242 patients who experienced GISOC (49.4%), of whom 33 (13.6%) did not receive surgery and 209 (86.4%) had a delay in receiving surgery. The trained risk model consisted of patient race (Indian, odds ratio [OR] = 0.24; White, OR = 0.23; v Black), comorbidity (OR = 2.29 v no comorbidity), and neoadjuvant therapy receipt (OR = 18.40 v nonreceipt). AUCs for the risk model were >0.800. CONCLUSION An accurate, setting-specific risk model and nomogram was developed for predicting GISOC in patients with RC. The nomogram can be implemented without the use of technology to identify patients at high risk for GISOC, who can then be targeted with risk-reduction interventions. The impact of the nomogram on existing surgical unit workflows requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gastrointestinal Cancer Research Group, Department of Surgery, University of KwaZulu-Natal, Durban, South Africa.
- Division of Health Systems and Public Health, Stellenbosch University, Cape Town, South Africa.
- Division of Applied Mathematics, Stellenbosch University, Cape Town, South Africa.
- Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
- Department of Health Sciences Education, University of Cape Town, Cape Town, South Africa.
- Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL.
ORCID-Profile: Yoshan Moodley, Shakeel Kader, Alfred I Neugut
Förderung
- NCI NIH HHS
Zitieren
APA
Moodley, Y., Brink, W., van Wyk, J., Kader, S., Wexner, S. D., Neugut, A. I., & Kiran, R. P. (2025). Risk Model for Predicting Gaps in Surgical Oncology Care Among Patients With Stage I-III Rectal Cancer From KwaZulu-Natal, South Africa. JCO Global Oncology. https://doi.org/10.1200/go-24-00480
Vancouver
Moodley Y, Brink W, van Wyk J, Kader S, Wexner SD, Neugut AI, et al. Risk Model for Predicting Gaps in Surgical Oncology Care Among Patients With Stage I-III Rectal Cancer From KwaZulu-Natal, South Africa. JCO Global Oncology. 2025. doi:10.1200/go-24-00480
BibTeX
@article{Moodley2025,
author = {Moodley, Yoshan and Brink, Willie and van Wyk, Jacqueline and Kader, Shakeel and Wexner, Steven D and Neugut, Alfred I and Kiran, Ravi P},
title = {Risk Model for Predicting Gaps in Surgical Oncology Care Among Patients With Stage I-III Rectal Cancer From KwaZulu-Natal, South Africa},
journal = {JCO Global Oncology},
year = {2025},
doi = {10.1200/go-24-00480}
}
EUVIMED